𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Changing clinical course of patients with malignant mesothelioma: Implications for FNA cytology and utility of immunocytochemical staining

✍ Scribed by Gordon H. Yu; Lori Soma; Stephen Hahn; Joseph S. Friedberg


Publisher
John Wiley and Sons
Year
2001
Tongue
English
Weight
221 KB
Volume
24
Category
Article
ISSN
8755-1039

No coin nor oath required. For personal study only.

✦ Synopsis


Abstract

The diagnosis of both local recurrences and distant metastases of mesothelioma can be accomplished by fine‐needle aspiration (FNA) biopsy. Although the previous history of mesothelioma provides strong support for recurrent/metastatic mesothelioma, other diagnostic possibilities (particularly adenocarcinoma) may require exclusion via special stains in some cases. In this study, we report on the morphologic findings in 13 cases of mesothelioma which underwent FNA (7 metastatic lesions, 6 local recurrences). In addition, immunohistochemical staining results for 7 cases with available material using antibodies directed against cytokeratin AE 1/3 and two antibodies reported to show consistently positive results in mesothelioma (calretinin and cytokeratin 5/6) are reported and compared to results seen for 10 cases of adenocarcinoma. All cases of mesothelioma and adenocarcinoma showed strong staining with cytokeratin AE 1/3. Three of 7 cases of mesothelioma showed strong staining with calretinin, while only focal staining was detected in 3 additional cases; only one case showed positive staining with cytokeratin 5/6. One of 10 cases of adenocarcinoma showed calretinin positivity; however, at least focal staining with cytokeratin 5/6 was seen in 4 cases. These results suggest that cytokeratin 5/6 is neither a sensitive nor specific stain for the diagnosis of mesothelioma in cytology material. Calretinin appears to be more specific for mesothelioma but showed disappointing sensitivity for this tumor, potentially limiting its diagnostic utility in FNA material. Diagn. Cytopathol. 24:322–327, 2001. © 2001 Wiley‐Liss, Inc.